Features | Partner Sites | Information | LinkXpress
Sign In
CARDIOSTIM
Ampronix
Primedic

Nurses Could Fill the Screening Gap in Rheumatoid Arthritis

By HospiMedica International staff writers
Posted on 03 Jul 2013
A nurse-led program of screening for comorbidities among patients with rheumatoid arthritis (RA) resulted in a doubling of the number of diagnostic and therapeutic actions, according to a new study.

Researchers at The Pierre-and-Marie-Curie University (Paris, France) conducted a study that prospectively enrolled 970 patients from 20 centers. Most were women, mean age was 58, disease duration averaged 11 years, and the majority had erosive disease. Most patients were being treated with methotrexate and some had used biologic therapies as well. The intervention consisted of an hour-long session in which nurses interviewed patients asking about adherence to recommendations from the French Society of Rheumatology for screening and managing the four major comorbidities of RA: cardiovascular disease, cancer, infections, and osteoporosis.

In any instance of nonadherence, the patient's physician was informed and was then left to decide on what action to take. Specific actions for cardiovascular disease included the introduction of lipid-lowering or antiplatelet therapy, smoking cessation, blood pressure measurements, patient purchase of a sphygmomanometer, and weight loss. Actions for cancer included mammograms and Pap smears, colonoscopy, and dermatology or urology referral, while actions for infections included pneumococcal, influenza, meningococcal, and hepatitis vaccinations. Actions relating to osteoporosis included dual-energy X-ray absorptiometry, calcium and vitamin D supplementation, and the introduction of anti-osteoporotic therapies.

The results showed that those randomized to the screening intervention had a mean of 4.54 actions, compared with 2.65 actions among controls, resulting in an incidence rate ratio (IRR) of 1.78 for actions resulting from the program. Specifically, for each of the comorbidities, the likelihood of an action being taken was higher in the nurse-led program, with the IRR for cardiovascular disease being 1.44, cancer, 1.65, infections, 1.78, and osteoporosis, 3.43. The study was presented at the annual meeting of the European League Against Rheumatism (EULAR), held during June 2013 in Madrid (Spain).

“Although we now have great treatments for rheumatoid arthritis, there is still a mortality gap compared with the general population. This results in part from the disease itself as well as from the treatments, but clearly it also relates to major comorbidities such as cardiovascular disease, which has an odds ratio of about 1.5 in patients with rheumatoid arthritis,” said lead author and study presenter Laure Gossec, MD, PhD. “For all these comorbidities we know what we should be doing—there are interventions for both screening and treatment; however, some studies have suggested that rheumatologists are not ordering the necessary screening tests, either because they haven't been trained to do so or because of time constraints.”

Related Links:
The Pierre-and-Marie-Curie University


Channels

Women's Health

view channel

Elective Cesarean Section Risks Outweigh Benefits

A new review states that cesarean section is associated with increased risks to both mother and child, and should only be performed when it is clearly advantageous. Researchers at Ludwig-Maximilians-Universität (LMU; Munich, Germany) conducted a review of studies to understand the rising worldwide trend of elective cesarean... Read more

Hospital News

view channel

Cygnet Healthcare Acquires Alpha Hospitals

Cygnet Healthcare (Sevenoaks, United Kingdom), part of Universal Health Services (UHS; King of Prussia, PA, USA), has acquired specialist psychiatric care provider Alpha Hospitals (Knaphill, United Kingdom). Alpha Hospitals is a leading provider of low and medium secure mental health care services in the UK.... Read more

Business

view channel
Image: The Centor 1-Clic vial (Photo courtesy of Centor).

Gerresheimer Buys Plastic Vials Maker Centor

Advanced healthcare glass and plastic products manufacturer Gerresheimer (Düsseldorf, Germany) has agreed to purchase plastic vial maker Centor (Perrysburg, OH, USA) for USD 725 million in cash.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.